Jade Biosciences, Inc. JBIO R2KR3KPHARMA
Company Overview
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.27.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +171.49% |
| 6 Months: | +41.64% |
| 3 Months: | +17.47% |
| 1 Month: | -10.52% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)40.37 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 25.9% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | JBIO Jade Biosciences, Inc. R2KR3KPHARMA | 19.90 | -7.57 | $1.21B | 0.00% | -34.07% | -38.32% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | -1.62M | -2.24M | -2.78M | -5.77M | -6.20M | -11.02M | -12.21M | -14.15M | -17.64M | -20.34M | -21.37M | -24.62M | -26.16M | -15.55M | -23.38M | -27.78M | -27.40M | -43.45M | -58.92M |
| Net Income | -1.44M | -2.20M | -2.31M | -2.78M | -5.78M | -6.18M | -10.91M | -11.99M | -13.59M | -16.52M | -19.02M | -19.56M | -23.19M | -24.77M | -16.87M | -38.17M | -32.13M | -25.18M | -40.37M | -55.77M |
| Diluted EPS | - | - | - | - | - | -0.26 | -0.45 | -0.49 | -0.56 | -0.67 | -0.76 | -0.71 | -0.83 | -0.86 | -5.35 | -12.10 | -0.86 | -0.48 | -0.57 | -0.76 |
| R&D Expense | - | 1.47M | 1.97M | 2.20M | 4.33M | 3.42M | 7.25M | 8.36M | 10.78M | 13.49M | 16.03M | 16.88M | 20.08M | 21.25M | 13.66M | 20.02M | 22.55M | 22.01M | 36.05M | 50.06M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -8.89M | -23.02M | -53.24M | -81.41M | -74.60M | -113.54M |
| Net Income | -9.61M | -22.96M | -51.51M | -75.52M | -69.63M | -127.41M |
| Diluted EPS | - | -1.87 | -2.10 | -2.87 | -2.44 | -3.19 |
| R&D Expense | 7.94M | 14.99M | 38.62M | 64.22M | 53.19M | 93.12M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Jun 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 4.71M | 175.36M | 135.30M | 127.42M | - | 72.80M | 349.78M |
| Current Assets | - | - | - | - | - | - | 69.65M | 348.82M |
| Cash & Equivalents | - | 4.57M | 54.20M | 22.40M | 23.49M | - | 69.39M | 88.44M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 1.77M | 2.94M | 8.56M | 17.96M | - | 119.60M | 17.26M |
| Current Liabilities | - | 1.77M | 2.55M | 7.78M | 17.64M | - | 12.00M | 16.54M |
| Long Term Debt | - | - | - | - | - | - | 107.60M | - |
| Total Debt | - | - | - | - | - | - | 107.60M | 724.00K |
| Total Equity | -3.64M | -13.34M | 172.42M | 126.74M | 109.46M | 1.00K | -46.80M | 332.52M |
| Shares Outstanding | - | - | - | - | - | - | 32.24M | 49.32M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.86M | -27.40M | -39.12M | -56.78M | -71.20M | -94.69M |
| Investing Cash Flow | - | -113.43M | 6.93M | 11.88M | 56.03M | -247.01M |
| Financing Cash Flow | 8.92M | 190.46M | 396.00K | 46.00M | 25.43M | 360.77M |
| Capital Expenditure | - | -181.00K | -195.00K | -142.00K | - | -196.00K |
| Free Cash Flow | - | -27.58M | -39.32M | -56.92M | - | -94.89M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 72.0% | -13.3% | -40.6% | -69.0% | 148.8% | -38.3% |
| ROCE % | -302.2% | -13.3% | -41.7% | -74.2% | -122.7% | -34.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.35% | 9.13M | $190.20M |
| 2 | Jupiter Topco LLC | 9.86% | 6.27M | $130.73M |
| 3 | Fairmount Funds Management LLC | 7.16% | 4.55M | $94.89M |
| 4 | RA Capital Management, L.P. | 5.77% | 3.67M | $76.51M |
| 5 | Venrock Adviser, LLC | 5.06% | 3.22M | $67.11M |
| 6 | Bellevue Group AG | 4.81% | 3.06M | $63.73M |
| 7 | Paradigm Biocapital Advisors LP | 4.49% | 2.86M | $59.55M |
| 8 | Blackrock Inc. | 4.40% | 2.80M | $58.38M |
| 9 | Franklin Resources, Inc. | 4.39% | 2.79M | $58.19M |
| 10 | State Street Corporation | 3.67% | 2.34M | $48.67M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for JBIO
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBETlZhQnQ4bE9PQjNDSEFpQlBudFBvNFlQYTZ5R2QyQ0s5bWFPOVRqa1I2Rk81TlBUWVRJb3h3ZV9WT1Q0Vzh1R0xGWUJxNHRJ?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNS2Q2VnBObkhxU3BndnRlekh3enItb2tPZEhIMXJsNDc5d0d0dGNPMHJSd3RRWkpCdWROVFVQUFExLUo4bi1sb2ZnX0N4aW44djlGUmQ2Z0RzeHpBZHg2c1hNWUd2Y2lvUDNMMUQzWmRiVndLVUJpVVdqVk9zYm40MXVpUnlXZnVwbVlWNH…
Jade Biosciences Company Profile & Introduction - Moomoo
<a href="https://news.google.com/rss/articles/CBMioAJBVV95cUxOWmo5d19TbTFNaFYtZllCYmdkNDNlNWFXRkNkNjFHTnBlMW5DSkxfVlpEOVNLcU5BUGtNWU1uaFBmU1pXZGZHeXlyb0VWdzFNcERIQVNjZldRLTl2ekprMktuX1dPbGVObHQzRTNJV2NvcFY4U05LazVtYTE2ejJ3Rk90RTJvbWNMd3FHcE…
Why This Biotech, Up 1,300% Over 17 Months, Just Took A Tumble - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNNTRudlo3b3E1ZkU1RW9ObkRzSmRRazZNcTdCcDVKS3J4ZG44anpOVGFjUlltSG1IcFAydGlmanBRaE5sd2VIazZxOTVtdnNnalhBNjdtOXVmY3lZUVZYQU9HMGdCcGpfTnZyOWNZQy1YNlZrMUd3RDUtMURrOTJZeDlPaktzdUNhR1BNZU…
Jade Biosciences: Duration Is The Real Product (NASDAQ:JBIO) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNRFhZM2t0ZFFpaS05Yk5OV1d2elRDOEEzWVRmUUVEdWdUMDJybFB3VHZlOFZMempHekxNdTBpaFRET1JJNXhoTDNUVktTV0ZieVM3S1dTODAyRzVwanFOUDZDWmF3RDJJeGFtMUN0UTNJbUFOVG1YNHBUN3hsM0Vrc0pmdDdGdDZfWU1KZX…
JBIO Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBtNjktNHdBMnBGWVJVWlhVZTVGYVZRTVZTN3BKd0FNd0NfSXhZanJRRG9FcEx1UlRER0RSQnJiVnVFXzA1LVA2bHRkRFpwZjlabzlPT1VpbjRDeklvWllHcVBGZXg4TFVvN1lXeFFkUG03N3lMTENLREF3?oc=5" target="_blank">JBI…
JBIO — Frequently Asked Questions
What is the current share price of Jade Biosciences, Inc. (JBIO)?
As of 2026-09-07 16:24 PDT, Jade Biosciences, Inc. (JBIO) trades at $19.90 on NasdaqCM. Its 52-week range is $6.77 to $26.85.
What is the market capitalisation of JBIO?
Jade Biosciences, Inc. (JBIO) has a market capitalisation of $1.21B on NasdaqCM.
What is the P/E ratio of JBIO?
JBIO trades at a trailing price-to-earnings (P/E) ratio of -7.57. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.66.
What is the return on equity (ROE) of JBIO?
JBIO has a return on equity (ROE) of -38.32%. Its return on capital employed (ROCE) is -34.07%.
Is JBIO a good stock to buy?
This page provides a data-driven analysis of Jade Biosciences, Inc. (JBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.